Stammdaten
Adaptive Biotechnologies Corporation, ein Unternehmen im kommerziellen Stadium, entwickelt eine Plattform für Immunmedizin zur Diagnose und Behandlung verschiedener Erkrankungen. Das Unternehmen bietet immunoSEQ, eine Plattform und Kernprodukt zur Immunsequenzierung, das zur Beantwortung von Fragen in der translationalen Forschung sowie zur Entdeckung neuer Prognose- und Diagnostiksignale verwendet wird; und T-Detect COVID zur Bestätigung früherer COVID-19-Infektionen. Das Unternehmen bietet außerdem clonoSEQ, ein klinisches Diagnoseprodukt zur Detektion und Überwachung minimaler Resterkrankung bei Patienten mit multiplem Myelom, B-Zell-akuter lymphoblastischer Leukämie und chronischer lymphozytärer Leukämie, sowie als CLIA-validierter klinisch entwickelter Test für Patienten mit anderen lymphoiden Krebserkrankungen; und immunoSEQ T-MAP COVID für Impfstoffentwickler und Forscher zur Messung der T-Zell-Immunantwort auf Impfstoffe. Das Unternehmen bietet außerdem eine Pipeline klinischer Produkte und Dienstleistungen zur Diagnose, Überwachung und Behandlung von Erkrankungen wie Krebs, Autoimmunerkrankungen und Infektionskrankheiten. Das Unternehmen bedient Anwendungen in der Life-Sciences-Forschung, klinischen Diagnostik und Wirkstofforschung. Adaptive Biotechnologies Corporation verfügt über strategische Partnerschaften mit Genentech, Inc. zur Entwicklung, Herstellung und Vermarktung von Neoantigen-gerichteten T-Zell-Therapien zur Behandlung verschiedener Krebsarten; und mit Microsoft Corporation zur Entwicklung diagnostischer Tests zur Früherkennung verschiedener Erkrankungen aus einem einzelnen Bluttest. Das Unternehmen war früher unter dem Namen Adaptive TCR Corporation bekannt und änderte seinen Namen im Dezember 2011 in Adaptive Biotechnologies Corporation. Adaptive Biotechnologies Corporation wurde 2009 gegründet und hat seinen Hauptsitz in Seattle, Washington. KI
Unternehmen & Branche
| Name | Adaptive Biotechnologies Corp |
|---|---|
| Ticker | ADPT |
| CIK | 0001478320 |
| Börse | Nasdaq |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | 00650F109 |
|---|---|
| ISIN | US00650F1093 |
| Typ | Common Stock |
| Marktkapitalisierung | 3,52 Mrd. USD |
| Beta | 2,14 |
Sitz & Kontakt
| Sitz (Inkorporation) | WA |
|---|---|
| Geschäftsadresse | 1165 EASTLAKE AVE E, 98109 SEATTLE, WA |
| Telefon | 206-659-0067 |
| EIN (IRS) | 27-0907024 |
Listing & Historie
| Listing-Börsen | Nasdaq |
|---|---|
| Fiskaljahr-Ende | 31.12. |
| SEC-Filer-Status | Large accelerated filer |
| Frühere Namen | Adaptive TCR Corp (bis 2011) |
Bewertung
| KBV (P/B) | 16,11 vs. 6,57 (2021) ▲ |
|---|---|
| KUV (P/S) | 12,73 vs. 25,71 (2021) ▼ |
| FCF-Rendite | -1,4 % vs. -6,4 % (2021) ▲ |
Qualität & Bilanz
| Bruttomarge | 74,2 % vs. 68,1 % (2021) ▲ |
|---|---|
| Operative Marge | -20,6 % vs. -135,4 % (2021) ▲ |
| Nettomarge | -21,5 % vs. -134,3 % (2021) ▲ |
| ROIC | -13,9 % vs. -29,0 % (2021) ▲ |
| Zinsdeckungsgrad | -4,8 |
| Forderungslaufzeit (DSO) | 66 T vs. 41 T (2021) ▲ |
| Lagerreichweite (DIO) | 50 T vs. 143 T (2021) ▼ |
| Verbindlichkeitslaufzeit (DPO) | 33 T vs. 24 T (2021) ▲ |
| Cash-Conversion-Cycle (CCC) | 84 T vs. 159 T (2021) ▼ |
Basis: SEC-XBRL-Jahresabschluss bis 31.12.2025, Multiples mit aktueller Marktkapitalisierung (trailing), Vergleich: GJ bis 2021. Kennzahlen erklärt →
Kennzahlen-Historie (5 Jahre) – Tabelle & Verlauf
| Kennzahl | 2021 | 2022 | 2023 | 2024 | 2025 | TTM* | Verlauf |
|---|---|---|---|---|---|---|---|
| Bewertung | |||||||
| KBV (P/B) | 6,57 | 2,36 | 2,31 | 4,37 | 11,41 | 16,29 | |
| KUV (P/S) | 25,71 | 5,90 | 4,18 | 4,95 | 9,02 | 11,93 | |
| FCF-Rendite | -6,4 % | -18,3 % | -23,5 % | -11,2 % | -2,0 % | -0,8 % | |
| Qualität & Bilanz | |||||||
| Bruttomarge | 68,1 % | 68,7 % | 55,6 % | 59,7 % | 74,2 % | 75,3 % | |
| Operative Marge | -135,4 % | -108,0 % | -133,3 % | -90,8 % | -20,6 % | -15,8 % | |
| Nettomarge | -134,3 % | -108,0 % | -132,3 % | -89,1 % | -21,5 % | -16,8 % | |
| ROIC | -29,0 % | -28,7 % | -41,9 % | -37,5 % | -13,9 % | -11,7 % | |
| Zinsdeckungsgrad | – | -47,2 | -16,5 | -14,0 | -4,8 | -4,0 | |
Basis: SEC-XBRL-Jahresabschlüsse, Multiples je Geschäftsjahr mit Marktkapitalisierung zum Bilanzstichtag (point-in-time).
TTM* = letzte zwölf Monate (vorläufig, ungeprüft): jüngstes Geschäftsjahr + laufendes YTD − Vorjahres-YTD aus den Quartalsberichten (10-Q); Bewertungs-Multiples gegen die aktuelle Marktkapitalisierung. Kein testierter Jahresabschluss.
Externe Quelle:
SEC EDGAR »
Externe Links: Yahoo Finance » · OnVista »
Glück Conviction Score™ ⓘ
ⓘ
ADPT
Adaptive Biotechnologies Corp
Effektiv
Neutral
Handelsvolumen
Mittel
Insider
0,0
Keine Insider-Käufe
Institutionell
49,4
49 neu, 102 erhöht, -383447K $ netto
Aktivist
0,0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,71% (Stand: 30.06.2026)
Score-Verlauf (90 Tage)
Konviktions-Verlauf — oben stark · Mitte neutral · unten schwach
Farbzonen = Stärkestufen (Sehr schwach … Sehr stark). Exit-Score unter der Schwelle = Timing-Ausstieg. Komponenten per Legende einblenden.
Kursverlauf (24 Monate)
Indexierte Darstellung (Start = 100) — die Kursform bleibt sichtbar, absolute Kurse sind angemeldeten Mitgliedern vorbehalten.
Technische Indikatoren
Technical-Score basiert auf 12 Indikatoren (Trend, Momentum, Volatilität, Position) mit fixen Gewichten — wird aktuell nur informativ angezeigt und fließt nicht in den Glück Conviction Score ein. Integration nach Backtest-Kalibrierung (P5).
| Indikator | Signal | Gewicht | Wert | Detail | Beitrag |
|---|---|---|---|---|---|
| Kurs vs SMA50 | Bullisch | 10 % | 17.55 | +24.6 % vs SMA50 | |
| Kurs vs SMA200 | Bullisch | 15 % | 16.24 | +34.6 % vs SMA200 | |
| SMA-Cross | Bullisch | 10 % | GOLDEN | vor 12 Tagen @ 22.37 | |
| EMA20 vs EMA50 | Bullisch | 5 % | 20.80 | EMA50: 18.60 | |
| MACD-Histogramm | Bärisch | 10 % | -0.057 | Bearisch | |
| RSI(14) | Neutral | 10 % | 58.8 | Neutral (30–70) | |
| Stoch %K(14) | Neutral | 5 % | 61.8 | Neutral | |
| ADX(14)+DI | Bullisch | 10 % | 44.7 | +DI: 26.0 / −DI: 10.1 | |
| Z-Score(60) | Bärisch | 5 % | 1.51 | Extrem überkauft | |
| 52W-Position | Bullisch | 5 % | 91.6 % | Hoch 22.92 / Tief 10.24 | |
| Bollinger(20,2σ) | Neutral | 5 % | 65.2 % | Upper 23.92 / Mid 20.96 / Lower 17.99 | |
| LinReg-Slope(60) | Bullisch | 10 % | +0.1729 | R²=0.85 / annualisiert +256.8 % |
Insider-Transaktionen (12 Monate) ⓘ
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-07-16 | BOBULSKY SUSAN | Officer, Chief Commercial Officer, MRD | Open Market Sale | -5.000 | 23,00 | -115.000,00 | -14,5% | |
| 2026-07-15 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -105.762 | 22,59 | -2.389.163,58 | -301,2% | |
| 2026-07-02 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -44.838 | 22,59 | -1.012.890,42 | -127,7% | |
| 2026-07-02 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -239.351 | 21,74 | -5.203.490,74 | -656,0% | |
| 2026-07-02 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -146.889 | 22,45 | -3.297.658,05 | -415,7% | |
| 2026-07-01 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -8.743 | 22,18 | -193.919,74 | -24,4% | |
| 2026-07-01 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -42.261 | 22,50 | -950.872,50 | -119,9% | |
| 2026-07-01 | BOBULSKY SUSAN | Officer, Chief Commercial Officer, MRD | Open Market Sale | -487 | 22,00 | -10.714,00 | -1,4% | |
| 2026-06-29 | BENZENO SHARON | Officer, Chief Commercial Ofc Imm Med | Open Market Sale | -154.768 | 21,14 | -3.271.795,52 | -412,5% | |
| 2026-06-26 | BENZENO SHARON | Officer, Chief Commercial Ofc Imm Med | Open Market Sale | -11.034 | 21,00 | -231.714,00 | -29,2% | |
| 2026-06-25 | GRIFFIN MICHELLE RENEE | Director | Open Market Sale | -52.084 | 20,18 | -1.051.055,12 | -132,5% | |
| 2026-06-25 | BOBULSKY SUSAN | Officer, Chief Commercial Officer, MRD | Open Market Sale | -5.000 | 20,50 | -102.500,00 | -12,9% | |
| 2026-06-16 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -6.160 | 18,01 | -110.941,60 | -14,0% | |
| 2026-06-15 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -100.000 | 17,37 | -1.737.000,00 | -219,0% | |
| 2026-06-11 | BOBULSKY SUSAN | Officer, Chief Commercial Officer, MRD | Open Market Sale | -5.000 | 19,00 | -95.000,00 | -12,0% | |
| 2026-06-04 | BOBULSKY SUSAN | Officer, Chief Commercial Officer, MRD | Open Market Sale | -11.000 | 18,00 | -198.000,00 | -25,0% | |
| 2026-06-04 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -39.741 | 17,49 | -695.070,09 | -87,6% | |
| 2026-05-18 | PISKEL KYLE | Officer, Chief Financial Officer | Open Market Sale | -3.115 | 13,04 | -40.619,60 | -5,1% | |
| 2026-04-27 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.037 | 14,23 | -270.896,51 | -34,2% | |
| 2026-04-24 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,02 | -267.221,20 | -33,7% | |
| 2026-04-23 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,74 | -261.884,40 | -33,0% | |
| 2026-04-22 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,13 | -269.317,80 | -34,0% | |
| 2026-04-21 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -30.941 | 14,66 | -453.595,06 | -57,2% | |
| 2026-04-20 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,55 | -277.323,00 | -35,0% | |
| 2026-04-17 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,57 | -277.704,20 | -35,0% | |
| 2026-04-16 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,18 | -270.270,80 | -34,1% | |
| 2026-04-15 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,61 | -278.466,60 | -35,1% | |
| 2026-04-14 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,56 | -277.513,60 | -35,0% | |
| 2026-04-13 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -15.722 | 12,95 | -203.599,90 | -25,7% | |
| 2026-04-13 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -3.338 | 14,08 | -46.999,04 | -5,9% | |
| 2026-04-10 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -18.660 | 12,75 | -237.915,00 | -30,0% | |
| 2026-04-10 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -400 | 13,48 | -5.392,00 | -0,7% | |
| 2026-04-09 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -2.100 | 14,44 | -30.324,00 | -3,8% | |
| 2026-04-09 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -16.960 | 13,79 | -233.878,40 | -29,5% | |
| 2026-04-08 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -100 | 15,48 | -1.548,00 | -0,2% | |
| 2026-04-08 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -22.564 | 15,07 | -340.039,48 | -42,9% | |
| 2026-04-08 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -10.000 | 14,85 | -148.500,00 | -18,7% | |
| 2026-04-08 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -37.263 | 15,19 | -566.024,97 | -71,4% | |
| 2026-04-08 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -30.841 | 14,83 | -457.372,03 | -57,7% | |
| 2026-04-07 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,56 | -258.453,60 | -32,6% | |
| 2026-04-06 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -83.332 | 14,41 | -1.200.814,12 | -151,4% | |
| 2026-04-06 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,33 | -273.129,80 | -34,4% | |
| 2026-04-02 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,60 | -278.276,00 | -35,1% | |
| 2026-04-01 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,45 | -275.417,00 | -34,7% | |
| 2026-03-31 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,45 | -256.357,00 | -32,3% | |
| 2026-03-30 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 12,63 | -240.727,80 | -30,3% | |
| 2026-03-27 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -2.738 | 12,49 | -34.197,62 | -4,3% | |
| 2026-03-27 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -16.322 | 13,48 | -220.020,56 | -27,7% | |
| 2026-03-26 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,12 | -269.127,20 | -33,9% | |
| 2026-03-25 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,27 | -271.986,20 | -34,3% | |
| 2026-03-24 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,70 | -261.122,00 | -32,9% | |
| 2026-03-23 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,83 | -263.599,80 | -33,2% | |
| 2026-03-20 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,37 | -254.832,20 | -32,1% | |
| 2026-03-19 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,18 | -251.210,80 | -31,7% | |
| 2026-03-18 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,18 | -251.210,80 | -31,7% | |
| 2026-03-17 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,40 | -255.404,00 | -32,2% | |
| 2026-03-16 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 13,41 | -255.594,60 | -32,2% | |
| 2026-03-13 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 12,96 | -247.017,60 | -31,1% | |
| 2026-03-12 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -5.400 | 13,43 | -72.522,00 | -9,1% | |
| 2026-03-12 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -13.660 | 12,63 | -172.525,80 | -21,8% | |
| 2026-03-11 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -122.523 | 13,17 | -1.613.627,91 | -203,4% | |
| 2026-03-11 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.060 | 14,08 | -268.364,80 | -33,8% | |
| 2026-03-11 | BENZENO SHARON | Officer, Chief Commercial Ofc Imm Med | Open Market Sale | -63.103 | 13,17 | -831.066,51 | -104,8% | |
| 2026-03-11 | PISKEL KYLE | Officer, Chief Financial Officer | Open Market Sale | -18.672 | 13,17 | -245.910,24 | -31,0% | |
| 2026-03-11 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -30.593 | 14,08 | -430.749,44 | -54,3% | |
| 2026-03-11 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -329.600 | 13,17 | -4.340.832,00 | -547,2% | |
| 2026-03-11 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -140.567 | 13,17 | -1.851.267,39 | -233,4% | |
| 2026-03-11 | GRIFFIN MICHELLE RENEE | Director | Open Market Sale | -15.394 | 13,91 | -214.130,54 | -27,0% | |
| 2026-03-11 | BOBULSKY SUSAN | Officer, Chief Commercial Officer, MRD | Open Market Sale | -41.338 | 13,17 | -544.421,46 | -68,6% | |
| 2026-03-11 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -329.600 | 13,17 | -4.340.832,00 | -547,2% | |
| 2026-03-11 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -140.666 | 13,17 | -1.852.571,22 | -233,6% | |
| 2026-03-10 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -19.460 | 14,68 | -285.672,80 | -36,0% | |
| 2026-03-09 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -30.941 | 14,79 | -457.617,39 | -57,7% | |
| 2026-03-06 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -30.941 | 15,14 | -468.446,74 | -59,1% | |
| 2026-03-05 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -30.941 | 16,00 | -495.056,00 | -62,4% | |
| 2026-03-05 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -38.074 | 15,09 | -574.536,66 | -72,4% | |
| 2026-03-04 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -30.941 | 16,60 | -513.620,60 | -64,8% | |
| 2026-03-03 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -2.380 | 16,15 | -38.437,00 | -4,8% | |
| 2026-03-03 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -24.423 | 15,49 | -378.312,27 | -47,7% | |
| 2026-03-03 | RUBINSTEIN JULIE | Officer, President and COO | Open Market Sale | -6.518 | 16,33 | -106.438,94 | -13,4% | |
| 2026-03-03 | GRIFFIN MICHELLE RENEE | Director | Open Market Sale | -48.044 | 15,30 | -735.073,20 | -92,7% | |
| 2026-03-03 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -14.233 | 16,52 | -235.129,16 | -29,6% | |
| 2026-03-03 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -50.703 | 15,49 | -785.389,47 | -99,0% | |
| 2026-03-02 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -10.000 | 15,72 | -157.200,00 | -19,8% | |
| 2026-03-02 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -289.024 | 15,82 | -4.572.359,68 | -576,4% | |
| 2026-02-27 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -182.891 | 15,99 | -2.924.427,09 | -368,7% | |
| 2026-02-04 | PISKEL KYLE | Officer, Chief Financial Officer | Open Market Sale | -2.145 | 18,46 | -39.596,70 | -5,0% | |
| 2026-02-03 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -8.120 | 19,00 | -154.280,00 | -19,5% | |
| 2026-02-02 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -34.668 | 18,60 | -644.824,80 | -81,3% | |
| 2026-02-02 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -124.998 | 18,44 | -2.304.963,12 | -290,6% | |
| 2026-01-12 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -79.590 | 17,73 | -1.411.130,70 | -177,9% | |
| 2026-01-12 | PISKEL KYLE | Officer, Chief Financial Officer | Open Market Sale | -4.290 | 18,00 | -77.220,00 | -9,7% | |
| 2026-01-06 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -10.000 | 16,44 | -164.400,00 | -20,7% | |
| 2026-01-05 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -124.998 | 15,59 | -1.948.718,82 | -245,7% | |
| 2026-01-02 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -3.125 | 16,08 | -50.250,00 | -6,3% | |
| 2025-12-22 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -4.394 | 17,50 | -76.895,00 | -9,7% | |
| 2025-12-22 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -4.394 | 17,50 | -76.895,00 | -9,7% | |
| 2025-12-15 | LO FRANCIS | Officer, Chief People Officer | Open Market Sale | -113.890 | 15,57 | -1.773.267,30 | -223,6% | |
| 2025-12-10 | HERSHBERG ROBERT | Director | Open Market Sale | -22.968 | 16,00 | -367.488,00 | -46,3% | |
| 2025-12-04 | BENZENO SHARON | Officer, Chief Commercial Ofc Imm Med | Open Market Sale | -12.604 | 16,85 | -212.377,40 | -26,8% | |
| 2025-12-04 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -10.000 | 16,61 | -166.100,00 | -20,9% | |
| 2025-12-03 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -27.212 | 18,61 | -506.415,32 | -63,8% | |
| 2025-12-01 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -124.998 | 18,94 | -2.367.462,12 | -298,5% | |
| 2025-11-28 | PISKEL KYLE | Officer, Chief Financial Officer | Open Market Sale | -162.820 | 19,50 | -3.174.990,00 | -400,3% | |
| 2025-11-26 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -35.736 | 19,68 | -703.284,48 | -88,7% | |
| 2025-11-21 | BENZENO SHARON | Officer, Chief Commercial Ofc Imm Med | Open Market Sale | -308.477 | 16,91 | -5.216.346,07 | -657,6% | |
| 2025-11-20 | BENZENO SHARON | Officer, Chief Commercial Ofc Imm Med | Open Market Sale | -297.925 | 16,54 | -4.927.679,50 | -621,2% | |
| 2025-11-17 | PISKEL KYLE | Officer, Chief Financial Officer | Open Market Sale | -238 | 14,05 | -3.343,90 | -0,4% | |
| 2025-11-12 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -1.867 | 15,00 | -28.005,00 | -3,5% | |
| 2025-11-11 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -1.237 | 14,57 | -18.023,09 | -2,3% | |
| 2025-11-10 | ROBINS HARLAN S | Officer, Chief Scientific Officer | Open Market Sale | -10.000 | 14,82 | -148.200,00 | -18,7% | |
| 2025-11-10 | ROBINS CHAD M | Director, Officer, CEO and Chairman | Open Market Sale | -86.161 | 14,73 | -1.269.151,53 | -160,0% |
Fondsaktivität (Vorquartalsvergleich) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für das aktuelle 13F-Quartal eingereicht — Werte können sich in den kommenden Wochen noch deutlich ändern.
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 29.993.708 | 0 | 29.993.708 | 416.312.667 | Neu | +100,0% | |
| BlackRock, Inc. | 13.303.025 | 0 | 13.303.025 | 184.645.993 | Neu | +100,0% | |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.094.144 | 0 | 6.094.144 | 84.586.719 | Neu | +100,0% | |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 5.436.718 | 0 | 5.436.718 | 75.461.646 | Neu | +100,0% | |
| WELLINGTON MANAGEMENT GROUP LLP | 3.857.422 | 0 | 3.857.422 | 53.541.017 | Neu | +100,0% | |
| GEODE CAPITAL MANAGEMENT, LLC | 3.636.054 | 0 | 3.636.054 | 50.476.677 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 3.242.077 | 0 | 3.242.077 | 45.000.029 | Neu | +100,0% | |
| STATE STREET CORP | 3.227.245 | 0 | 3.227.245 | 44.794.161 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 3.017.341 | 0 | 3.017.341 | 41.880.713 | Neu | +100,0% | |
| BNP Paribas Asset Management Holding S.A. | 2.688.081 | 0 | 2.688.081 | 37.310.564 | Neu | +100,0% | |
| ARK Investment Management LLC | 2.092.969 | 0 | 2.092.969 | 29.050.406 | Neu | +100,0% | |
| FRED ALGER MANAGEMENT, LLC | 2.063.146 | 0 | 2.063.146 | 28.636.466 | Neu | +100,0% | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.995.202 | 0 | 1.995.202 | 27.693.404 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 1.965.610 | 0 | 1.965.610 | 27.282.666 | Neu | +100,0% | |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1.881.183 | 0 | 1.881.183 | 26.111.000 | Neu | +100,0% | |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.750.601 | 0 | 1.750.601 | 24.298.342 | Neu | +100,0% | |
| Aristotle Atlantic Partners, LLC | 1.714.346 | 0 | 1.714.346 | 23.795.122 | Neu | +100,0% | |
| PRINCIPAL FINANCIAL GROUP INC | 1.704.887 | 0 | 1.704.887 | 23.663.831 | Neu | +100,0% | |
| Amova Asset Management Americas, Inc. | 1.595.370 | 0 | 1.595.370 | 22.143.736 | Neu | +100,0% | |
| Sumitomo Mitsui Trust Group, Inc. | 1.595.370 | 0 | 1.595.370 | 22.143.736 | Neu | +100,0% | |
| NORTHERN TRUST CORP | 1.392.332 | 0 | 1.392.332 | 19.325.568 | Neu | +100,0% | |
| Divisadero Street Capital Management, LP | 1.318.661 | 0 | 1.318.661 | 18.303.015 | Neu | +100,0% | |
| Nuveen, LLC | 1.304.160 | 0 | 1.304.160 | 18.101.741 | Neu | +100,0% | |
| Capricorn Fund Managers Ltd | 1.291.773 | 0 | 1.291.773 | 17.929.809 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 1.227.917 | 0 | 1.227.917 | 17.043.488 | Neu | +100,0% | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.145.682 | 0 | 1.145.682 | 15.902.066 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 1.081.366 | 0 | 1.081.366 | 15.009.360 | Neu | +100,0% | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 1.072.331 | 0 | 1.072.331 | 14.883.954 | Neu | +100,0% | |
| Aberdeen Group plc | 1.070.627 | 0 | 1.070.627 | 14.860.303 | Neu | +100,0% | |
| Point72 Asset Management, L.P. | 1.021.808 | 0 | 1.021.808 | 14.182.695 | Neu | +100,0% | |
| Blue Water Life Science Advisors, LP | 1.010.145 | 0 | 1.010.145 | 14.020.813 | Neu | +100,0% | |
| MORGAN STANLEY | 967.120 | 0 | 967.120 | 13.423.648 | Neu | +100,0% | |
| KENNEDY CAPITAL MANAGEMENT LLC | 931.522 | 0 | 931.522 | 12.929.525 | Neu | +100,0% | |
| WASATCH ADVISORS LP | 576.266 | 0 | 576.266 | 12.360.906 | Neu | +100,0% | |
| OBERWEIS ASSET MANAGEMENT INC/ | 806.951 | 0 | 806.951 | 11.200.480 | Neu | +100,0% | |
| TUDOR INVESTMENT CORP ET AL | 786.281 | 0 | 786.281 | 10.913.580 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 785.783 | 0 | 785.783 | 10.906.668 | Neu | +100,0% | |
| JENNISON ASSOCIATES LLC | 753.073 | 0 | 753.073 | 10.452.654 | Neu | +100,0% | |
| Catalio Capital Management, LP | 722.784 | 0 | 722.784 | 10.032.242 | Neu | +100,0% | |
| Rhenman & Partners Asset Management AB | 720.000 | 0 | 720.000 | 9.993.600 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 710.682 | 0 | 710.682 | 9.864.266 | Neu | +100,0% | |
| Connor, Clark & Lunn Investment Management Ltd. | 649.627 | 0 | 649.627 | 9.016.823 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 639.377 | 0 | 639.377 | 8.874.553 | Neu | +100,0% | |
| Hillsdale Investment Management Inc. | 625.217 | 0 | 625.217 | 8.678.012 | Neu | +100,0% | |
| PEREGRINE CAPITAL MANAGEMENT LLC | 393.095 | 486.641 | -93.546 | 8.431.888 | Reduziert | -19,2% | |
| Trexquant Investment LP | 571.584 | 0 | 571.584 | 7.933.586 | Neu | +100,0% | |
| FMR LLC | 567.032 | 0 | 567.032 | 7.870.399 | Neu | +100,0% | |
| SEI INVESTMENTS CO | 560.554 | 0 | 560.554 | 7.780.492 | Neu | +100,0% | |
| FIRST TRUST ADVISORS LP | 554.584 | 0 | 554.584 | 7.697.625 | Neu | +100,0% | |
| Parkman Healthcare Partners LLC | 551.815 | 0 | 551.815 | 7.659.192 | Neu | +100,0% |
Top-Fondshalter (Stand: 30.06.2026) ⓘ
⚠ Vorläufige Daten: Erst 1693 von typischerweise 8373 Fonds (20 %) haben für dieses Quartal eingereicht. Vollständigkeit erwartet bis 14.08.2026. Auswertungen (NEW/INC/DEC) sind noch zu konservativ — viele Spätfiler erscheinen aktuell als „Exits".
| Fonds | Anteile | Vorquartal (Stk) | Δ | Wert (USD) | Anteil (%) | Stimmkontrolle | Verlauf |
|---|---|---|---|---|---|---|---|
| WASATCH ADVISORS LP | 576.266 | 0 | +100,0% | 12.360.906 | 41,81 | 100 % | 1 Q |
| PEREGRINE CAPITAL MANAGEMENT LLC | 393.095 | 486.641 | -19,2% | 8.431.888 | 28,52 | 37 % | 13 Q |
| Y-Intercept (Hong Kong) Ltd | 135.137 | 0 | +100,0% | 2.898.689 | 9,80 | 100 % | 5 Q |
| Edge Wealth Management LLC | 90.000 | 90.000 | 0,0% | 1.930.500 | 6,53 | 100 % | 17 Q |
| Diversified Trust Co | 48.908 | 45.776 | +6,8% | 1.049.076 | 3,55 | 0 % | 5 Q |
| Assenagon Asset Management S.A. | 23.883 | 0 | +100,0% | 512.290 | 1,73 | 100 % | 7 Q |
| Investors Towarzystwo Funduszy Inwestycyjnych Spolka Akcyjna | 23.400 | 23.400 | 0,0% | 501.930 | 1,70 | 100 % | 3 Q |
| Merit Financial Group, LLC | 22.330 | 0 | +100,0% | 478.979 | 1,62 | 0 % | 1 Q |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC | 18.136 | 19.237 | -5,7% | 381.944 | 1,29 | 3 % | 6 Q |
| GAMMA Investing LLC | 13.113 | 13.181 | -0,5% | 281.274 | 0,95 | 100 % | 10 Q |
| Net Worth Advisory Group | 10.932 | 12.073 | -9,5% | 234.501 | 0,79 | 100 % | 2 Q |
| Avior Wealth Management, LLC | 10.408 | 12.915 | -19,4% | 223.252 | 0,76 | 0 % | 6 Q |
| LANARK FINANCIAL, INC. | 7.534 | 7.480 | +0,7% | 161.604 | 0,55 | 100 % | 4 Q |
| DLK Investment Management, LLC | 10.100 | 0 | +100,0% | 36.562 | 0,12 | 100 % | 3 Q |
| GoalVest Advisory LLC | 830 | 830 | 0,0% | 17.804 | 0,06 | 100 % | 17 Q |
| Ares Financial Consulting, LLC | 715 | 715 | 0,0% | 15.337 | 0,05 | 100 % | 3 Q |
| Versant Capital Management, Inc | 494 | 494 | 0,0% | 10.596 | 0,04 | 100 % | 9 Q |
| Owl Creek Wealth Partners LLC | 437 | 437 | 0,0% | 9.374 | 0,03 | 0 % | 2 Q |
| True Wealth Design, LLC | 267 | 267 | 0,0% | 5.728 | 0,02 | 0 % | 8 Q |
| Physician Wealth Advisors, Inc. | 265 | 236 | +12,3% | 5.685 | 0,02 | 0 % | 7 Q |
Halter-Trend (6 Quartale)
| Periode | Status | Halter | Anteile (Mio) | Wert (Mio $) |
|---|---|---|---|---|
| 30.06.2026 | vorl. | 29 | 1,5 | 30 |
| 31.03.2026 | ✓ | 295 | 161,2 | 2.139 |
| 31.12.2025 | ✓ | 283 | 155,9 | 2.429 |
| 30.09.2025 | ✓ | 268 | 149,3 | 2.185 |
| 30.06.2025 | ✓ | 239 | 149,2 | 1.708 |
| 31.03.2025 | ✓ | 221 | 161,0 | 1.182 |
Top 10 Neueinsteiger
| Fonds | Anteile | Wert (USD) |
|---|---|---|
| BNP Paribas Asset Management Holding S.A. | 2.688.081 | 37.310.564 |
| Capricorn Fund Managers Ltd | 1.291.773 | 17.929.809 |
| JANE STREET GROUP, LLC | 682.182 | 9.468.686 |
| Granite Investment Partners, LLC | 500.061 | 6.940.847 |
| SummitTX Capital, L.P. | 317.624 | 4.408.621 |
| Counterpoint Mutual Funds LLC | 307.268 | 4.264.880 |
| RENAISSANCE TECHNOLOGIES LLC | 239.800 | 3.328.424 |
| PERCEPTIVE ADVISORS LLC | 152.500 | 2.116.700 |
| TWO SIGMA INVESTMENTS, LP | 118.200 | 1.640.616 |
| TWINBEECH CAPITAL LP | 54.277 | 753.365 |
Top 10 Aufstocker
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 3.857.422 | 1.692.095 | +78.1 % | 53.541.017 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 5.436.718 | 1.376.237 | +33.9 % | 75.461.646 |
| MILLENNIUM MANAGEMENT LLC | 1.081.366 | 1.063.009 | +5790.8 % | 15.009.360 |
| Divisadero Street Capital Management, LP | 1.318.661 | 957.317 | +264.9 % | 18.303.015 |
| T. Rowe Price Investment Management, Inc. | 919.278 | 916.150 | +29288.7 % | 12.760 |
| Point72 Asset Management, L.P. | 1.021.808 | 818.733 | +403.2 % | 14.182.695 |
| Nuveen, LLC | 1.304.160 | 517.513 | +65.8 % | 18.101.741 |
| LORD, ABBETT & CO. LLC | 3.536.103 | 455.344 | +14.8 % | 49.081 |
| BANK OF AMERICA CORP /DE/ | 1.227.917 | 421.645 | +52.3 % | 17.043.488 |
| PANAGORA ASSET MANAGEMENT INC | 515.926 | 351.189 | +213.2 % | 7.161.053 |
Top 10 Verkäufer
| Fonds | Anteile | Δ Anteile | Δ % | Wert (USD) |
|---|---|---|---|---|
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.566.213 | -2.821.148 | -64.3 % | 21.741 |
| JENNISON ASSOCIATES LLC | 753.073 | -1.921.595 | -71.8 % | 10.452.654 |
| PBU - The Pension Fund of Early Childhood & Youth Educators | 378.069 | -1.272.234 | -77.1 % | 5.247.598 |
| DIMENSIONAL FUND ADVISORS LP | 188.338 | -1.194.586 | -86.4 % | 2.614.132 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 1.750.601 | -1.009.786 | -36.6 % | 24.298.342 |
| DEUTSCHE BANK AG\ | 785.783 | -948.682 | -54.7 % | 10.906.668 |
| Blue Water Life Science Advisors, LP | 1.010.145 | -755.000 | -42.8 % | 14.020.813 |
| ALGERT GLOBAL LLC | 362.710 | -521.661 | -59.0 % | 5.034 |
| NEXT CENTURY GROWTH INVESTORS LLC | 504.346 | -439.251 | -46.6 % | 7.000.322 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.995.202 | -426.887 | -17.6 % | 27.693.404 |
Zusätzlich aktuell von 166 Mutual Funds/ETFs gehalten (N-PORT). Alle Fondsgesellschaften & ihre 4-Quartals-Bewegungen →
Aktivisten & Großaktionäre (13D/13G) ⓘ
| Datum | Investor | Typ | Anteil | Aktien | Δ | Δ-Balken |
|---|---|---|---|---|---|---|
| 15.05.2026 | Viking Global Equities II LP | Passiv (13G/A) | 0,30 % | 440.046 | 0,00 pp | |
| 15.05.2026 | VIKING GLOBAL INVESTORS LP (+2) | Passiv (13G/A) | 18,80 % | 29.993.708 | Neu | |
| 15.05.2026 | VIKING GLOBAL PERFORMANCE LLC | Passiv (13G/A) | 13,80 % | 22.002.189 | Neu | |
| 15.05.2026 | Viking Long Fund Master Ltd. (+1) | Passiv (13G/A) | 5,00 % | 7.991.519 | -0,50 pp | |
| 15.05.2026 | Viking Global Equities Master Ltd. | Passiv (13G/A) | 13,50 % | 21.562.143 | -1,40 pp | |
| 26.03.2026 | The Vanguard Group | Passiv (13G/A) | Ausstieg | 0 | -7,21 pp | |
| 21.01.2026 | BlackRock, Inc. | Passiv (13G/A) | 7,90 % | 11.992.448 | +1,20 pp | |
| 09.07.2025 | Rubric Capital Management LP (+1) | Passiv (13G/A) | 4,12 % | 6.256.847 | -5,64 pp | |
| 06.06.2025 | ARK Investment Management LLC (+1) | Passiv (13G/A) | 2,90 % | 4.398.669 | -2,30 pp | |
| 14.05.2025 | ARK Investment Management LLC (+1) | Passiv (13G) | 5,20 % | 7.732.570 | +1,21 pp | |
| 07.05.2025 | ARK Investment Management LLC | Passiv (13G/A) | 3,99 % | 6.067.809 | -2,40 pp | |
| 17.04.2025 | BlackRock, Inc. | Passiv (13G/A) | 6,70 % | 9.940.846 | Neu | |
| 14.02.2025 | ARK Investment Management LLC | Passiv (13G/A) | 6,39 % | 9.424.074 | -0,04 pp | |
| 13.02.2025 | Nikko Asset Management Americas, Inc. | Passiv (13G/A) | 4,63 % | 6.833.137 | -0,61 pp | |
| 04.02.2025 | Sumitomo Mitsui Trust Group, Inc. (+1) | Passiv (13G/A) | 4,60 % | 6.833.137 | Neu | |
| 27.01.2025 | Millennium Group Management LLC (+2) | Passiv (13G/A) | 4,30 % | 6.292.634 | -2,10 pp | |
| 27.01.2025 | Integrated Core Strategies (US) LLC | Passiv (13G/A) | 3,80 % | 5.622.214 | -2,50 pp | |
| 13.11.2024 | Rubric Capital Management LP (+1) | Passiv (13G) | 9,76 % | 14.400.000 | Neu | |
| 13.11.2024 | Matrix Capital Management Company LP (+1) | Passiv (13G/A) | 0,44 % | 650.000 | -7,76 pp | |
| 12.11.2024 | The Vanguard Group | Passiv (13G/A) | 7,21 % | 10.639.440 | 0,00 pp | |
| 08.11.2024 | Nikko Asset Management Americas, Inc. | Passiv (13G) | 5,24 % | 7.733.884 | Neu | |
| 05.11.2024 | Sumitomo Mitsui Trust Group, Inc. (“SMTG”) (+1) | Passiv (13G) | 5,24 % | 7.733.884 | Neu | |
| 04.11.2024 | The Vanguard Group | Passiv (13G) | 7,21 % | 10.639.440 | -1,61 pp | |
| 11.10.2024 | Integrated Core Strategies (US) LLC | Passiv (13G/A) | 6,30 % | 9.303.890 | +1,10 pp | |
| 11.10.2024 | Millennium Group Management LLC (+2) | Passiv (13G/A) | 6,40 % | 9.400.573 | +1,10 pp | |
| 28.05.2024 | Millennium Group Management LLC (+2) | Passiv (13G) | 5,30 % | 7.750.133 | Neu | |
| 28.05.2024 | Integrated Core Strategies (US) LLC | Passiv (13G) | 5,20 % | 7.731.846 | Neu | |
| 14.02.2024 | Viking Global Equities II LP | Passiv (13G/A) | 0,30 % | 440.046 | 0,00 pp | |
| 14.02.2024 | Viking Global Performance LLC | Passiv (13G/A) | 15,20 % | 22.002.189 | -0,40 pp | |
| 14.02.2024 | Viking Long Fund Master Ltd. (+1) | Passiv (13G/A) | 5,50 % | 7.991.519 | -0,20 pp | |
| 14.02.2024 | Viking Global Equities Master Ltd. | Passiv (13G/A) | 14,90 % | 21.562.143 | -0,40 pp | |
| 14.02.2024 | Viking Global Investors LP (+3) | Passiv (13G/A) | 20,70 % | 29.993.708 | -0,60 pp | |
| 13.02.2024 | The Vanguard Group | Passiv (13G/A) | 8,82 % | 12.767.684 | +0,57 pp | |
| 29.01.2024 | ARK | Passiv (13G/A) | 8,85 % | 12.806.513 | Neu | |
| 26.01.2024 | . BlackRock, Inc. | Passiv (13G) | 7,90 % | 11.421.554 | Neu | |
| 10.02.2023 | ARK Investment Management LLC | Passiv (13G) | 6,43 % | 9.201.245 | Neu | |
| 09.02.2023 | The Vanguard Group | Passiv (13G/A) | 8,25 % | 11.794.168 | +0,43 pp | |
| 12.09.2022 | T. ROWE PRICE ASSOCIATES, INC. | Passiv (13G/A) | 2,90 % | 4.081.518 | -7,10 pp | |
| 12.09.2022 | T. ROWE PRICE NEW HORIZONS FUND, INC. | Passiv (13G/A) | 1,20 % | 1.849.399 | -4,80 pp | |
| 14.02.2022 | Viking Global Investors LP (+3) | Passiv (13G/A) | 21,30 % | 29.993.708 | -0,60 pp |
Finanzkennzahlen (SEC XBRL) ⓘ
Währung:
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2026-03-31 | 10-Q | 70.874.000 $ | -20.033.000 $ | -0,13 $ | 505.943.000 $ | 216.340.000 $ |
| 2025-12-31 | 10-K | 276.976.000 $ | -59.499.000 $ | -0,39 $ | 512.736.000 $ | 218.793.000 $ |
| 2025-09-30 | 10-Q | 93.973.000 $ | 9.546.000 $ | 0,06 $ | 490.610.000 $ | 204.435.000 $ |
| 2025-06-30 | 10-Q | 58.879.000 $ | -25.614.000 $ | -0,17 $ | 496.637.000 $ | 179.717.000 $ |
| 2025-03-31 | 10-Q | 52.443.000 $ | -29.852.000 $ | -0,20 $ | 510.852.000 $ | 190.423.000 $ |
| 2024-12-31 | 10-K | 178.957.000 $ | -159.492.000 $ | -1,08 $ | 539.376.000 $ | 202.709.000 $ |
| 2024-09-30 | 10-Q | 46.435.000 $ | -32.071.000 $ | -0,22 $ | 558.506.000 $ | 223.773.000 $ |
| 2024-06-30 | 10-Q | 43.190.000 $ | -46.222.000 $ | -0,31 $ | 584.872.000 $ | 241.603.000 $ |
| 2024-03-31 | 10-Q | 41.873.000 $ | -47.507.000 $ | -0,33 $ | 620.323.000 $ | 274.913.000 $ |
| 2023-12-31 | 10-K | 170.276.000 $ | -225.250.000 $ | -1,56 $ | 661.134.000 $ | 308.399.000 $ |
| 2023-09-30 | 10-Q | 37.919.000 $ | -50.300.000 $ | -0,35 $ | 717.682.000 $ | 361.732.000 $ |
| 2023-06-30 | 10-Q | 48.926.000 $ | -47.810.000 $ | -0,33 $ | 764.540.000 $ | 396.036.000 $ |
| 2023-03-31 | 10-Q | 37.647.000 $ | -57.699.000 $ | -0,40 $ | 791.463.000 $ | 424.020.000 $ |
| 2022-12-31 | 10-K | 185.308.000 $ | -200.191.000 $ | -1,40 $ | 856.617.000 $ | 464.165.000 $ |
| 2022-09-30 | 10-Q | 47.830.000 $ | -45.281.000 $ | -0,32 $ | 884.208.000 $ | 487.840.000 $ |
| 2022-06-30 | 10-Q | 43.660.000 $ | -52.046.000 $ | -0,37 $ | 806.633.000 $ | 518.304.000 $ |
| 2022-03-31 | 10-Q | 38.620.000 $ | -62.736.000 $ | -0,44 $ | 858.193.000 $ | 553.205.000 $ |
| 2021-12-31 | 10-K | 154.344.000 $ | -207.279.000 $ | -1,48 $ | 923.344.000 $ | 603.992.000 $ |
| 2021-09-30 | 10-Q | 39.467.000 $ | -55.903.000 $ | -0,40 $ | 992.607.000 $ | 651.509.000 $ |
| 2021-06-30 | 10-Q | 38.505.000 $ | -49.301.000 $ | -0,35 $ | 1.033.374.000 $ | 693.181.000 $ |
Umsatz nach Segmenten & Regionen ⓘ
Geschäftssegmente
| Segment | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | Anteil | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| Immune Medicine Service Revenue | 41,3 Mio. | 13,5 Mio. | 42,6 Mio. | 62,8 Mio. | – | 100,0 % | +205,9% | |
| Sequencing Revenue | – | – | – | – | 78,9 Mio. | – | – | |
| Development Revenue | – | – | – | – | 75,4 Mio. | – | – | |
| Development Support Revenue | – | – | – | – | 65,4 Mio. | – | – | |
| Development Revenue Regulatory Milestones | – | – | – | – | 10,0 Mio. | – | – |
Quartalsergebnisse (Earnings) ⓘ
| Quartal | Stichtag | Verkündet | Umsatz | EPS |
|---|---|---|---|---|
| Q1 2026 | 31.03.2026 | 05.05.2026 | 70,9 Mio. USD | -0,13 |
| Q3 2025 | 30.09.2025 | 05.11.2025 | 94,0 Mio. USD | 0,06 |
| Q2 2025 | 30.06.2025 | 05.08.2025 | 58,9 Mio. USD | -0,17 |
| Q1 2025 | 31.03.2025 | 01.05.2025 | 52,4 Mio. USD | -0,20 |
| Q3 2024 | 30.09.2024 | 07.11.2024 | 46,4 Mio. USD | -0,22 |
| Q2 2024 | 30.06.2024 | 01.08.2024 | 43,2 Mio. USD | -0,31 |
| Q1 2024 | 31.03.2024 | 07.05.2024 | 41,9 Mio. USD | -0,33 |
| Q3 2023 | 30.09.2023 | 09.11.2023 | 37,9 Mio. USD | -0,35 |
| Q2 2023 | 30.06.2023 | 02.08.2023 | 48,9 Mio. USD | -0,33 |
Einreichungs-Historie (10-K / 10-Q / 20-F / 6-K)
SEC-Einreichungs-Historie der letzten sechs Jahre (Datum = US-Kalendertag,
SEC/ET): Quartalsberichte (10-Q) und Jahresberichte (10-K); ausländische
Emittenten (ADR/Foreign Private Issuer) reichen stattdessen Jahresberichte
(20-F/40-F) und Zwischenmitteilungen (6-K) ein — dort liegt im SEC-Index
keine Berichtsperiode vor, Periode und Verzögerung bleiben leer. Die Spalte „Verzögerung" zeigt die
Tage zwischen Berichtsstichtag und tatsächlicher Einreichung.
Suffix /A kennzeichnet nachträgliche Berichtigungen.
| Eingereicht (US) | Form | Berichtsperiode | Verzögerung | |
|---|---|---|---|---|
| 05.05.2026 | 10-Q | 31.03.2026 | 35 Tage | SEC » |
| 26.02.2026 | 10-K | 31.12.2025 | 57 Tage | SEC » |
| 05.11.2025 | 10-Q | 30.09.2025 | 36 Tage | SEC » |
| 05.08.2025 | 10-Q | 30.06.2025 | 36 Tage | SEC » |
| 01.05.2025 | 10-Q | 31.03.2025 | 31 Tage | SEC » |
| 03.03.2025 | 10-K | 31.12.2024 | 62 Tage | SEC » |
| 07.11.2024 | 10-Q | 30.09.2024 | 38 Tage | SEC » |
| 01.08.2024 | 10-Q | 30.06.2024 | 32 Tage | SEC » |
| 07.05.2024 | 10-Q | 31.03.2024 | 37 Tage | SEC » |
| 29.02.2024 | 10-K | 31.12.2023 | 60 Tage | SEC » |
| 09.11.2023 | 10-Q | 30.09.2023 | 40 Tage | SEC » |
| 02.08.2023 | 10-Q | 30.06.2023 | 33 Tage | SEC » |
| 03.05.2023 | 10-Q | 31.03.2023 | 33 Tage | SEC » |
| 14.02.2023 | 10-K | 31.12.2022 | 45 Tage | SEC » |
| 03.11.2022 | 10-Q | 30.09.2022 | 34 Tage | SEC » |
| 03.08.2022 | 10-Q | 30.06.2022 | 34 Tage | SEC » |
| 04.05.2022 | 10-Q | 31.03.2022 | 34 Tage | SEC » |
| 15.02.2022 | 10-K | 31.12.2021 | 46 Tage | SEC » |
| 03.11.2021 | 10-Q | 30.09.2021 | 34 Tage | SEC » |
| 04.08.2021 | 10-Q | 30.06.2021 | 35 Tage | SEC » |
| 05.05.2021 | 10-Q | 31.03.2021 | 35 Tage | SEC » |
| 24.02.2021 | 10-K | 31.12.2020 | 55 Tage | SEC » |
| 10.11.2020 | 10-Q | 30.09.2020 | 41 Tage | SEC » |
| 10.08.2020 | 10-Q | 30.06.2020 | 41 Tage | SEC » |
Proxy-/Governance-Filings
Proxy-Statements (SEC DEF-14A-Familie) der letzten sechs Jahre: reguläre HV-Einladungen zur Aktionärsversammlung, Aktivisten-Proxy-Fights (contested / Non-Management-Solicitation) und M&A-Abstimmungen.
| Datum (US) | Kategorie | HV-Termin (US) | Stichtag (US) | Form | |
|---|---|---|---|---|---|
| 24.04.2026 | HV-Einladung | — | — | DEFA14A | SEC » |
| 24.04.2026 | HV-Einladung | 05.06.2026 Jahres-HV | 07.04.2026 | DEF 14A | SEC » |
| 29.04.2025 | HV-Einladung | — | — | DEFA14A | SEC » |
| 29.04.2025 | HV-Einladung | 10.06.2025 Jahres-HV | 15.04.2025 | DEF 14A | SEC » |
| 24.05.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2024 | HV-Einladung | — | — | DEFA14A | SEC » |
| 26.04.2024 | HV-Einladung | 07.06.2024 Jahres-HV | 10.04.2024 | DEF 14A | SEC » |
| 01.06.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2023 | HV-Einladung | — | — | DEFA14A | SEC » |
| 28.04.2023 | HV-Einladung | 09.06.2023 Jahres-HV | 12.04.2023 | DEF 14A | SEC » |
| 22.04.2022 | HV-Einladung | — | — | DEFA14A | SEC » |
| 22.04.2022 | HV-Einladung | 10.06.2022 Jahres-HV | 14.04.2022 | DEF 14A | SEC » |
| 23.04.2021 | HV-Einladung | — | — | DEFA14A | SEC » |
| 23.04.2021 | HV-Einladung | 11.06.2021 Jahres-HV | 14.04.2021 | DEF 14A | SEC » |
Datum = US-Einreichungsdatum (SEC EDGAR, ET). HV-Termin = Datum der Aktionärsversammlung, Stichtag (Record Date) = Nachweisstichtag für die Stimmberechtigung (aus dem Dokument extrahiert).
Kritische 8-K Meldungen ⓘ
| Datum | Meldung | Tags | Schwere | Filing | Auszug |
|---|---|---|---|---|---|
| 22.06.2026 | Volltext-Klassifikation | Fortführungszweifel | EXTREM | SEC | concern |
| 02.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | such filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain… |
| 13.06.2023 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | 13(a) of the Exchange Act. ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors… |
| 17.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 05.03.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 27.01.2021 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 16.10.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 26.06.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
| 18.02.2020 | Item 5.02 — Abgang Schlüsselpersonen | – | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers… |
8-K-Ereignisse (KI)
🔒 Die vollständige KI-Einordnung je 8-K ist Teil des Kunden-Abos — freischalten.
| Datum | Ereignis | Sentiment | Materialität | Zusammenfassung | Filing |
|---|---|---|---|---|---|
| 22.06.2026 | Finanzierung/Anleihe | 0,15 | 65 | Adaptive Biotechnologies hat convertible notes im Umfang von 156,9 Mio. $ ausgegeben und damit ihre Revenue-Interest-Vereinbarung mit OrbiMe… 🔒 | SEC |
| 09.06.2026 | HV-Abstimmung | 0,00 | 20 | Hauptversammlung am 5. Juni 2026 mit Wahl von zwei Klasse-I-Direktoren (Robert Hershberg und Katey Owen) und beratender Abstimmung zur Vorst… 🔒 | SEC |
| 05.05.2026 | Quartalszahlen | 0,00 | 55 | Adaptive Biotechnologies gab Finanzergebnisse für das erste Quartal 2026 ab. | SEC |
| 05.02.2026 | Quartalszahlen | 0,00 | 55 | Adaptive Biotechnologies berichtete über Finanzergebnisse für Q4 und Geschäftsjahr 2025. | SEC |
| 12.01.2026 | Quartalszahlen | 0,00 | 40 | Adaptive Biotechnologies veröffentlichte Geschäftsergebnisse und präsentierte Investor-Informationen via Regulation FD Disclosure. | SEC |
Fail-to-Deliver (6 Monate) ⓘ
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-06-30 | 3.100 | 21,40 | 66.340 |
| 2026-06-18 | 84 | 16,78 | 1.410 |
| 2026-06-12 | 234 | 18,73 | 4.383 |